Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years

Current Medical Research and Opinion

Volumn 24, Issue 1, 2008, Pages 275-286

  Klonoff, David C ^a   Buse, John B ^b   Nielsen, Loretta L ^c   Guan, Xuesong ^c   Bowlus, Christopher L ^d   Holcombe, John H ^e   Wintle, Matthew E ^c   Maggs, David G ^c  

^a DIABETES RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c AMYLIN PHARMACEUTICALS INC   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e ELI LILLY AND COMPANY   (United States)

Author keywords

ALT; AST; Exenatide; Exendin 4; HDLC; Incretin mimetic; LDL C; NAFLD; Triglycerides; Type 2 diabetes

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BIOLOGICAL MARKER; CHOLESTEROL; EXENDIN 4; LIPID; METFORMIN; PLACEBO; SULFONYLUREA; TRIACYLGLYCEROL;

ADULT; AGED; BLOOD ANALYSIS; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; RANDOMIZED CONTROLLED TRIAL; UPPER RESPIRATORY TRACT INFECTION;

AGED; BIOMARKERS, PHARMACOLOGICAL; BLOOD PRESSURE; BODY WEIGHT; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; LIVER; MALE; MIDDLE AGED; OBESITY; PEPTIDES; PLACEBOS; RISK FACTORS; TIME FACTORS; VENOMS;

EID: 38549162147     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079907X253870     Document Type: Conference Paper

References (34)

1. Anderson JW, Kendall CW, Jenkins DJ. Importance of weight management in type 2 diabetes: review with meta-analysis of clinical studies. J Am Coll Nutr 2003;22:331-9
2. Maggio CA, Pi-Sunyer FX. Obesity and type 2 diabetes. Endocrinol Metab Clin North Am 2003;32:805-22
3. Stein CJ, Colditz GA. The epidemic of obesity. J Clin Endocrinol Metab 2004;89:2522-5
4. Mokdad AH, Ford ES, Bowman BA, et al. Diabetes trends in the U.S.: 1990-1998. Diabetes Care 2000;23:1278-83
5. Mokdad AH, Ford ES, Bowman BA, et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 2003;289:76-9
6. Bray GA. Medical consequences of obesity. J Clin Endocrinol Metab 2004;89:2583-9
7. Yki-Järvinen H, Westerbacka J. The fatty liver and insulin resistance. Curr Molec Med 2005;5:287-95
8. Buse JB, Ginsberg HN, Bakris GL, et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus. Diabetes Care 2007;30:162-72
9. Williamson DF, Thompson TJ, Thun M, et al. Intentional weight loss and mortality among overweight individuals with diabetes. Diabetes Care 2000;23:1499-1504
10. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53
11. UK Prospective Diabetes Study Group. UK Prospective Diabetes Study 28. A randomized trial of efficacy of early addition of metformin in sulfonylurea-treated type 2 diabetes. Diabetes Care 1998;21:87-92
12. Koro CM, Bowlin SJ, Bourgeois N, et al. Glycemic control from 1988 to 2000 among U.S. adults diganosed with type 2 diabetes. Diabetes Care 2004;27:17-20
13. Kirpichnikov D, McFarlane SI, Sowers JR. Metformin: an update. Ann Intern Med 2002;137:25-33
14. DeFronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 1995;333:541-9
15. American Gastroenterological Association. Medical position statement: nonalcoholic fatty liver disease. Gastroenterology 2002;123:1702-4
16. American Gastroenterological Association. Technical review on nonalcoholic fatty liver disease. Gastroenterology 2002;123:1705-25
17. Raz I, Eldor R, Cernea S, et al. Diabetes: insulin resistance and derangements in lipid metabolism. Cure through intervention in fat transport and storage. Diabetes Metab Res Rev 2005;21:3-14
18. Webb DM, Wintle M, Malone JK. Exenatide effects on glucose metabolism and metabolic disorders common to overweight and obese patients with type 2 diabetes. Drug Devel Res 2006;67:666-76
19. Nauck MA, Duran S, Kim D, et al. A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a noninferiority study. Diabetologia 2007;50:259-67
20. Zinman B, Hoogwerf BJ, Garcia SD, et al. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes. Ann Intern Med 2007;146:477-85
21. Mack CM, Laugero KD, Liu Q, et al. Therapeutic applications of incretin mimetics for metabolic diseases: preclinical studies. Drug Dev Res 2006;67:553-8
22. Buse JB, Henry RR, Han J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004;27:2628-35
23. DeFronzo RA, Ratner RE, Han J, et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005;28:1092-1100
24. Kendall DM, Riddle MC, Rosenstock J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005;28:1083-91
25. Buse JB, Klonoff DC, Nielsen LL, et al. Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients widi type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials. Clin Ther 2007;29:139-53
26. Blonde L, Klein EJ, Han J, et al. Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes Metab 2006;8:436-47
27. Declaration of Helsinski: Recommendations guiding medical physicians in biomedical research involving human subjects. JAMA 1997;277:925-6
28. Prati D, Taioli E, Zanella A, et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 2002;137:1-10
29. Yki-Järvinen H. Combination therapies with insulin in type 2 diabetes. Diabetes Care 2001;24:758-67
30. Purnell JQ, Weyer C. Weight effect of current and experimental drugs for diabetes mellitus: from promotion to alleviation of obesity. Treat Endocrinol 2003;2:33-47
31. Makimattila S, Nikkila K, Yki-Jarvinen H. Causes of weight gain during insulin therapy with and without metformin in patients with Type II diabetes mellitus. Diabetologia 1999;42:406-12
32. Angulo P. Current best treatment for non-alcoholic fatty liver disease. Exp Opinion Pharmacother 2003;4:611-23
33. Ding X, Saxena NK, Lin S, et al. Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice. Hepatology 2006;43:173-81
34. Tushuizen ME, Bunck MC, Pouwels PJ, et al. Incretin mimetics as a novel therapeutic option for hepatic steatosis. Liver Int 2006;26:1015-17